Arthrex Eclipse™ Shoulder Prosthesis
Status: | Active, not recruiting |
---|---|
Conditions: | Arthritis, Osteoarthritis (OA) |
Therapuetic Areas: | Rheumatology |
Healthy: | No |
Age Range: | 21 - Any |
Updated: | 12/14/2018 |
Start Date: | January 2013 |
End Date: | December 2020 |
A Prospective, Randomized, Multicenter Study Comparing the Safety and Effectiveness of Arthrex's Eclipse™ Shoulder Prothesis to the Univers™ II Shoulder Prosthesis in Patients With a Degenerative Joint Disease
A Prospective, Randomized, Multicenter Study comparing the Safety and Effectiveness of
Arthrex's Eclipse™ Shoulder to the Univers™ II Shoulder Prosthesis in patients with a
degenerative joint disease.
Arthrex's Eclipse™ Shoulder to the Univers™ II Shoulder Prosthesis in patients with a
degenerative joint disease.
The purpose of this study is to demonstrate non-inferiority of the Arthrex Eclipse™ Shoulder
Prosthesis to the Arthrex Univers™ II Shoulder Prosthesis for the treatment of degenerative
joint disease in subjects who are candidates for total shoulder replacement. Non-inferiority
in terms of safety and effectiveness will be measured by a 2 year composite clinical success
(CCS) that requires functional improvement, radiographic success, absence of reoperations and
revision, and lack of serious device-related adverse events.
Prosthesis to the Arthrex Univers™ II Shoulder Prosthesis for the treatment of degenerative
joint disease in subjects who are candidates for total shoulder replacement. Non-inferiority
in terms of safety and effectiveness will be measured by a 2 year composite clinical success
(CCS) that requires functional improvement, radiographic success, absence of reoperations and
revision, and lack of serious device-related adverse events.
Inclusion Criteria:
- The subject is > 21 years of age
- The subject has continued symptoms in target shoulder despite at least 3 months of
other treatment modalities(e.g.: anti-inflammatory, physical therapy and steroid
injections)
- The subject has a diagnosis in the target shoulder of one or more of the following:
osteoarthritis, avascular necrosis, post-traumatic arthritis, or rheumatoid arthritis.
- The subject presents with pain and functional impairment in the index shoulder,
measured by an Adjusted Constant Score of ≤50. Note: The Adjusted Constant Score will
be calculated from the raw Constant Score to establish patient eligibility.
- The subject is willing to receive implantation of the Arthrex™ Shoulder Prosthesis or
Univers™ II Shoulder Prosthesis.
- The subject must be physically and mentally willing and able to comply with all study
procedures (including follow-up visits and radiographic assessments) until the
conclusion of the study.
- The subject has been informed of the nature of the study and provided written consent
as approved by the sites local Institutional Review Board or Ethic Review Board.
Exclusion Criteria:
- The subject is likely a candidate for hemi-humeral arthroplasty (i.e.: Avascular
Necrosis of the humeral head without glenoid involvement (Stages 0-3): Rotator Cuff
Deficient Shoulder: Glenoid Bone deficiency/deformity that precludes glenoid
replacement (Walch Type B2 or C) or Fractures of the Proximal Humerus, without Glenoid
involvement.
- The subject has immature bone as defined by the absence of cancellous bone patterning,
a mature, thick cortex, and stress lines within the cancellous bone.
- The subject has obvious defects in bone quality, such as cysts or lesions, in the
humeral head of the target shoulder, as demonstrated by radiographic evaluation.
- The subject has a target shoulder a rotator cuff that is not intact and not
reconstructible.
- The subject has Irreducible 3- and 4- part proximal humeral fractures of the target
shoulder.
- The subject has documented history of foreign-body sensitivity.
- Subject with positive pregnancy test, or lactating, or intends to become pregnant
during treatment period
- The subject has history of Schizophrenia, Bipolar Disorder and/or Major Depressive
Disorder as defined by DSM IV.
- The subject is skeletally immature demonstrated radiographically by incomplete closure
of proximal humeral epiphyses.
- The subject is at high risk for poor healing or confounding outcomes [(i.e.:
clinically significant renal, hepatic, cardiac hematologic disease or endocrine
disease)]
- The subject is on immune-stimulating or immunosuppressive agents
- The subject has co-morbidity that reduces life expectancy < 36 month.
- The subject seeking or receiving workman's compensation for shoulder injury,
- The subject is > 350 lbs.
- The subject engaged in heavy labor (e.g. repetitive lifting in the excess of more than
50 lbs.)
- The subject has had surgery in the affected shoulder in the last 12 months (with the
exception of diagnostic arthroscopy without reconstruction or repair procedures)
- The subject is engaged in active sports participation. (e.g. weight lifting involving
upper extremities or involved in contact sports)
- The subject is taking medications known to potentially interfere with bone/soft tissue
healing (e.g. steroids with the exception of topical and/or inhalers)
- The subject is a prisoners or wards of the state
- The subject has a history of alcohol and/or substance abuse as defined by DSM IV
(Diagnostic and Statistical Manual Diploma in Social Medicine)
- The subject has an active or chronic infection, either systemic or local.
- The subject has pathologic fractures of the affected shoulder
- The subject has acute trauma of the affected shoulder
- The subject has osteoporosis defined as a bone density T score of < or = -2.5. (A
screening Questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk
Estimation) and MORES (Male Osteoporosis Risk Estimation Score), will be used to
screen patients who require a DEXA (dual energy x-ray absorptiometry) bone mineral
density measurement.
We found this trial at
16
sites
Click here to add this to my saved trials
3000 Fairway Drive
Altoona, Pennsylvania 16602
Altoona, Pennsylvania 16602
Principal Investigator: Joshua Port, MD
Phone: 814-944-4532
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Columbia, South Carolina 29203
Click here to add this to my saved trials
Columbus, Ohio 43215
Principal Investigator: Nathan Long, D.O.
Phone: 614-566-8394
Click here to add this to my saved trials
Click here to add this to my saved trials
Duluth, Minnesota 55805
Principal Investigator: Jeffery Klassen, MD
Phone: 218-786-4126
Click here to add this to my saved trials
East Syracuse, New York 13057
Principal Investigator: Kevin Setter, M.D.
Phone: 315-464-8618
Click here to add this to my saved trials
Click here to add this to my saved trials
Medford, Oregon 97504
Principal Investigator: Patrick Denard, MD
Phone: 701-430-2097
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19107
Principal Investigator: Joseph Abboud
Phone: 267-339-3566
Click here to add this to my saved trials
Click here to add this to my saved trials
Salisbury, Maryland 21804
Principal Investigator: Thomas A Brandon, M.D.
Phone: 410-749-4154
Click here to add this to my saved trials
Click here to add this to my saved trials